Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a August 19, 2026 6:00 PM EDT
Company Participants
Joshua Higa – Director of Investor Relations & Corporate Communications
Emil Kakkis – Founder, President, CEO & Director
Eric Crombez – Chief Medical Officer & Executive VP
Erik Harris – Executive VP & Chief Commercial Officer
Howard Horn – Executive VP of Corporate Strategy & CFO
Conference Call Participants
Anupam Rama – JPMorgan Chase & Co, Research Division
Ross Fladeland – Cantor Fitzgerald & Co., Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Tejas Wein – Barclays Bank PLC, Research Division
Lydia Erdman – Goldman Sachs Group, Inc., Research Division
Maxwell Skor – Morgan Stanley, Research Division
Amit Dayal – H.C. Wainwright & Co, LLC, Research Division
Ashleigh Acker
Benjamin Burnett – Wells Fargo Securities, LLC, Research Division
James Stamos – Jefferies LLC, Research Division
Presentation
Operator
Good afternoon, and welcome to the Ultragenyx Pharmaceutical Conference Call to discuss the U.S. Food and Drug Administration approval of GENGLYCOS known as DTX401 for the treatment of glycogen storage disease type 1a or GSD1a.
[Operator Instructions]
And it is now my pleasure to turn the call over to Joshua Higa, Chief of Staff and Vice President of Investor Relations. Thank you, Joshua. Please go ahead.
Joshua Higa
Director of Investor Relations & Corporate Communications
Thank you, and good afternoon, everyone. We appreciate you all for making time to join us on such short notice to discuss this important day for Ultragenyx. The press release we issued announcing the approval of GENGLYCOS is available on our website at ultragenyx.com.
Joining me on today’s call are Emil Kakkis, Chief Executive Officer and President; Eric Crombez, Chief Medical Officer; Erik Harris, Chief Commercial Officer; and Howard Horn, Chief Financial Officer.
Before we begin, I’d like to remind everyone that during today’s call, we
